Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals is a late-stage drug development company with the mission to develop and commercialise pentosan polysulfate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, dege
Short position
Paradigm Biopharmaceuticals (ASX:PAR) has 0.09% of its shares on issue reported as short positions as of 5 Oct 2026, or about 593,492 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has risen 0.09 percentage points. Its highest recorded short interest was 4.77% in March 2022. PAR is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Paradigm Biopharmaceuticals (PAR) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $80.2Kvs n/a (FY25)
- Yahoo Finance, as at 1 Oct 2026
- NPAT
- −$56.3Mvs n/a (FY25)
- Yahoo Finance, as at 1 Oct 2026
- EPS (diluted)
- −$0.15vs −$0.060 (FY25)
- Yahoo Finance, as at 1 Oct 2026
- Rev YoY
- n/aFY
- EPS YoY
- n/aTTM
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- 84.9%
- Operating margin
- −76,434.1%
- Net margin
- −70,282.3%
- FCF margin
- −55,118.8%
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net cash (excl. leases)
- $8.4M
- Net debt / EBITDA
- n/a
- Current ratio
- 1.1×
- Interest cover
- −24.9×
- Cash dividends paid / net profit
- n/a
- Market cap
- $143.3M
- P/E
- n/a
- P/B
- 41.3×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 1 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $80.2K | n/a | $65.8K | $46.8K |
| Gross profit | $68.0K | n/a | $56.8K | $27.9K |
| Operating income | −$61.3M | n/a | −$65.2M | −$60.0M |
| EBITDA | −$53.7M | n/a | −$58.5M | −$51.9M |
| EBIT | −$53.9M | n/a | −$58.6M | −$51.9M |
| Interest expense | $2.5M | n/a | $14.4K | $16.4K |
| Pretax income | −$56.3M | n/a | −$58.7M | −$51.9M |
| Tax | $0 | n/a | $0 | $0 |
| NPAT | −$56.3M | n/a | −$58.7M | −$51.9M |
| Net interest income | −$2.0M | n/a | $392.6K | $1.4M |
| EPS basic | −$0.15 | −$0.060 | −$0.20 | −$0.18 |
| EPS diluted | −$0.15 | −$0.060 | −$0.20 | −$0.18 |
| Shares | 584.8M | n/a | 350.4M | 289.7M |
Financial reports
The company's own filings, newest first
- Appendix 4E and 2026 Annual ReportAnnual Results28 Aug 2026via asx_announcements
- June 2026 Quarterly Activities Report & Appendix 4CQuarterly Report30 Jul 2026via asx_announcements
- March 2026 Quarterly Activities Report & Appendix 4CQuarterly Report27 Apr 2026via asx_announcements
- Appendix 4D and Half Year ReportHalf Year Results27 Feb 2026via asx_announcements
- December 2025 Quarterly Activities Report & Appendix 4CQuarterly Report30 Jan 2026via asx_announcements
- September 2025 Quarterly Activities Report & Appendix 4CQuarterly Report30 Oct 2025via asx_announcements
- Appendix 4E and 2025 Annual ReportAnnual Results29 Aug 2025via asx_announcements
- June 2025 Quarterly Activities Report & Appendix 4CQuarterly Report29 Jul 2025via asx_announcements
- March 2025 Quarterly Activities Report & Appendix 4CQuarterly Report29 Apr 2025via asx_announcements
- Appendix 4D and Half Year ReportHalf Year Results28 Feb 2025via asx_announcements
Showing 10 of 96 reports